Ysios Capital

Ysios Capital

Last activity: 12.06.2024
Invests in categories: MedTechBioTechDevelopmentHealthTechTechnologyDrugHumanPlatformProductIT
Ysios Capital, a leading Spanish venture capital firm, provides private equity financing to early and mid-stage life science companies that develop disruptive therapeutic products and platform technologies. Founded in 2008, Ysios Capital manages over USD 420M through three dedicated funds in life sciences and is led by a team of professionals experienced in building biotech companies.
Location: Spain, Autonomous Community of the Basque Country, San Sebastián
Employees: 11-50
Founded date: 2008
Investment Type: Venture Capital
Investment Stage: Series A; Series B; Series C; Private Equity

Portfolio 36

DateNameWebsiteTotal RaisedLocation
12.06.2024Memo Thera...memo-therapeutics.com$106.22MSwitzerlan...
21.03.2024Engrail Th...engrail.com$253MUnited Sta...
21.03.2024Fusion Pha...fusionpharma.com$195.91MCanada, On...
08.03.2024NEURONA TH...neuronatherapeutics.com$192.6MUnited Sta...
08.07.2023Tagworks P...tagworkspharma.com$65MNetherland...
14.09.2022SparingVis...sparingvision.com$202.94MFrance, Il...
03.07.2022Mineralys ...mineralystx.com$470MCanada
07.06.2022Minoryx Th...minoryx.com$106.01MSpain, Cat...
21.02.2022SpliceBiosplice.bio$56.9MSpain, Cat...
Show more

Persons 21

DateFirst NameLast NameTitleLinkedInLocation
-MaríaVega de Se...Controllerlinkedin.c...-
-WenWen ChengHead of Le...linkedin.c...-
-KarenWagnerManaging P...linkedin.c...Zurich
-AntoniRibasVenture Pa...-
-LanceBermanVenture Pa...linkedin.c...-
-PamelaKleinVenture Pa...linkedin.c...-
-JoanPerellóVenture Pa...linkedin.c...-
Show more

Mentions in press and media 160

07.05.2024Memo Therapeutics raises additional CHF20 million Schlieren-based Memo Therapeutics is a late-stage biotech company developing therapeutic antibodies for patients with viral infections and cancer. MTx’s lead program, AntiBKV, is a highly effective and safe neutralizing antibody to treat B...
19.03.2024Engrail Therapeutics raises $157M Series BEngrail Therapeutics, a precision neuroscience company focused on the development of transformational therapies to improve the lives of patients, today announced that it has closed an oversubscribed $157 million Series B financing round. Th...
07.11.2023Ysios Capital invierte en la Serie A de €57M de Kynexis para tratar el deterioro cognitivo en pacientes con esquizofrenia07/11/2023 Nota de prensa YSIOS CAPITAL INVIERTE EN LA SERIE A DE €57M DE KYNEXIS PARA TRATAR EL DETERIORO COGNITIVO EN PACIENTES CON ESQUIZOFRENIA Ysios Capital invierte en la Serie A de 57 millones de euros de Kynexis para tratar el de...
26.06.2023Dutch-based Tagworks Pharmaceuticals raises €59.5M to design effective, safe systemic therapiesThe Netherlands-based Tagworks Pharmaceuticals, a company that claims to be a pioneer of Click-to-Release chemistry to deliver effective and safer systemic therapies, announced on Thursday, June 22, that it has raised $65M (approximately €5...
22.06.2023Ysios Capital lidera una inversión de $64M en Tagworks Pharmaceuticals junto con Gilde22/06/2023 Nota de prensa YSIOS CAPITAL LIDERA UNA INVERSIÓN DE $64M EN TAGWORKS PHARMACEUTICALS JUNTO CON GILDE Ysios Capital, gestora española líder en inversiones en el sector biotecnológico, ha anunciado hoy su participación en la ro...
04.04.2023Ysios Capital’s portfolio company Adcendo announces extension of Series A financing to 82M€ to ensure broad development of first-in-class ADC pipeline04/04/2023 Nota de prensa YSIOS CAPITAL’S PORTFOLIO COMPANY ADCENDO ANNOUNCES EXTENSION OF SERIES A FINANCING TO 82M€ TO ENSURE BROAD DEVELOPMENT OF FIRST-IN-CLASS ADC PIPELINE Adcendo ApS (“Adcendo”), a biotech company focused on the de...
14.02.2023Ysios Capital anuncia la salida a bolsa en el NASDAQ de su participada Mineralys Therapeutics14/02/2023 Nota de prensa YSIOS CAPITAL ANUNCIA LA SALIDA A BOLSA EN EL NASDAQ DE SU PARTICIPADA MINERALYS THERAPEUTICS Ysios Capital, gestora española líder en inversiones en el sector biotecnológico, ha anunciado hoy la salida a bolsa ...
19.01.2023Ysios Capital refuerza su equipo con promociones internas y un nuevo Venture Partner19/01/2023 Nota de prensa YSIOS CAPITAL REFUERZA SU EQUIPO CON PROMOCIONES INTERNAS Y UN NUEVO VENTURE PARTNER Ysios Capital, gestora de capital riesgo (venture capital) en el sector de ciencias de la vida, ha anunciado hoy las promocion...
20.12.2022Ralf van den Berg se incorpora a Inbiomotion, participada por Ysios, como CEO20/12/2022 Nota de prensa RALF VAN DEN BERG SE INCORPORA A INBIOMOTION, PARTICIPADA POR YSIOS, COMO CHIEF OPERATING OFFICER Inbiomotion SL, compañía biotecnológica que desarrolla un biomarcador único basado en un solo gen para el tratami...
16.11.2022SpliceBio recibe el premio a la “Serie A del año” en los European Lifestars awards16/11/2022 Nota de prensa SPLICEBIO RECIBE EL PREMIO A LA “SERIE A DEL AÑO” EN LOS EUROPEAN LIFESTARS AWARDS SpliceBio, compañía biotecnológica de terapia génica con sede en Barcelona basada en tecnología desarrollada en la Universidad d...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In